Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

basic toxicokinetics, other
Type of information:
other: Expert statement
Adequacy of study:
key study
Study period:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Evalation of all available evidence for indications of toxicokinetic behavior
Justification for type of information:
According to the REACH-regulation all available information should be evaluated without requiring specific studies.

Data source

Reference Type:
other company data
Report date:

Materials and methods

Objective of study:
other: Evaluation of ADME properties of Pigment Brown 25
Test guideline
no guideline available
GLP compliance:

Results and discussion

Main ADME resultsopen allclose all
No absorption expected
Due to lack of absorption: no distribution expected
No metabolism expected in relevant amounts
All of substance is expected to move through the intestinal tract unchanged

Toxicokinetic / pharmacokinetic studies

Details on absorption:
A prerequisite for a relevant absorption is that the substance can be dissolved in either aqueous (e.g., gastrointestinal fluid, blood plasma, sweat) or lipophilic (e.g., lipoproteins, lipid membranes, triglycerides) media or in both. PB25 can be considered insoluble because it has an extremely low solubility in water and n-octanol (17 µg/L and 240 µg/L, respectively). Therefore, it is unlikely that PB25 becomes systemically bioavailable after oral, dermal or inhalation exposure.

Based on the sub-acute oral toxicity study with read-across source substance C.I. Pigment Red 176, absorption of toxicologically significant amounts via the gastrointestinal tract is considered unlikely, since C.I. Pigment Red 176 did not show any effects on inner organs and blood or urine.
The skin sensitisation study with C.I. Pigment Brown 25 as well as that with C.I. Pigment Red 176 indicate no local dermal bioavailability.

Systemic availability also seems to be negligible after dermal exposure since no systemic signs of intoxication were seen after administration of 2000 mg C.I. Pigment Brown 25 per kg body weight to rabbit skin in the acute dermal toxicity study. Dermal absorption is, therefore, considered unlikely.

In the unlikely event of exposure to aerosolized pigment in respirable form, the substance is considered to behave like an inert dust. Therefore, the deposited pigment particles will mostly be cleared from the lung via the mucocilliary transport. As the pigment will not dissolve in the lung surfactant, the only way the pigment can enter the body is via phagocytosis of pigment particles by lung macrophages followed by migration of the macrophages into the interstitium and into the draining lymph nodes. However, the internal dose delivered via this mechanism can be considered negligible.
Details on distribution in tissues:
The Repeated Dose 28-d oral toxicity study and the Reproduction/Developmental Toxicity Screening Test with read-across source substance C.I. Pigment Red 176 did not indicate any relevant histopathological changes in any of the investigated organs. This may indicate that the pigment either does not affect special organs as targets, i.e., is non-toxic, or is not distributed within the body in significant amounts. Likewise, pathological and histopathological changes were also not observed in an older and albeit incompletely documented 18-d Repeated Dose toxicity study on C.I. Pigment Brown 25 itself. As indicated above, the physico-chemical parameters of the pigment support the conclusion that the pigment is not absorbed into the body and thus does not become systemically available. There were also no other signs of deposition of the pigment in any organ including excretory organs, like the kidney, indicating that even exposure to high doses of the pigment does not lead to bioaccumulation in special compartments of the body.
Based on the available information on absorption, distribution of the test material in the body in significant amounts is unlikely and specific hotspots of distribution cannot be identified.
Thus, it is concluded, that C.I. Pigment Brown 25 is not systemically available at relevant concentrations within the organism. There were no signs of bioaccumulation of the test material. This view is supported by the physical-chemical properties (solubility in water and octanol).
Details on excretion:
Considering the physico-chemical properties and the molecular structure and size of the material and the absence of any indication of absorption and/or metabolism it is assumed that excretion, if any, is likely to occur via faeces.

Metabolite characterisation studies

Metabolites identified:
Details on metabolites:
SSince the solution of the substance in cellular fluid or cellular membranes is a prerequisite for its metabolism, it is unlikely that the insoluble pigment becomes accessible for metabolizing systems in relevant amounts.

The results of the mutagenicity tests provide useful indications for qualitative consideration of the metabolic fate of C.I. Pigment Brown 25. In the mutagenicity tests, the pigment proved to be non-mutagenic in the absence as well as in the presence of an exogenous metabolizing system, indicating that the pigments are not converted into genotoxic metabolites. This conclusion is also supported by the lack of any morphological and histopathological changes of organs involved in xenobiotic metabolism, such as the liver, in the 28-d Repeated Dose toxicity study with read-across source substance C.I. Pigment Red 176 and in the incompletely documented 18-d Repeated Dose toxicity study on C.I. Pigment Brown 25. Furthermore, the missing skin or eye irritating or skin sensitizing properties argue against any interaction with biological material.
Therefore, C.I. Pigment Brown 25 is considered to just pass through the intestinal tract without significant metabolism.

Bioaccessibility (or Bioavailability)

Bioaccessibility (or Bioavailability) testing results:
There are no indications of bio-accesability of Pigment Red 176.

Applicant's summary and conclusion

Based on all available data, C.I. Pigment Brown 25 does not exhibit conspicuous toxicokinetic behaviour in the sense of accumulative and/or delayed effects with regard to the individual parameters absorption, distribution, metabolism and excretion. C.I. Pigment Brown 25 is most probably not absorbed from the gastrointestinal tract in significant amounts, nor is it absorbed following dermal administration.

Executive summary:

Based on the available database on C.I. Pigment Brown 25 and the read-across source substance C.I. Pigment Red 176, relevant information exists to make a qualitative evaluation of the toxicokinetic profile of this compound. This is in line with animal welfare considerations because additional animal tests can be avoided by such an evaluation.

The physico-chemical parameters of C.I. Pigment Brown 25, and in particular its very low solubility in both water and octanol, indicate that the substance will not be absorbed via the dermal or the oral route. The absence of all toxicological and histopathological effects in the available study reports further substantiates this finding. In the absence of absorption of PB 25, distribution and metabolism of are not expected to occur. Any PB 25 that enters the body via the gastro-intestinal tract is expected to be excreted unchanged in the faeces.